Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics
CHRS Price/Volume Stats
| Current price | $4.12 | 52-week high | $14.11 |
| Prev. close | $4.05 | 52-week low | $3.60 |
| Day low | $4.06 | Volume | 617,982 |
| Day high | $4.27 | Avg. volume | 1,501,124 |
| 50-day MA | $6.44 | Dividend yield | N/A |
| 200-day MA | $7.94 | Market Cap | 331.88M |
CHRS Stock Price Chart Interactive Chart >
CHRS POWR Grades
- Momentum is the dimension where CHRS ranks best; there it ranks ahead of 78.35% of US stocks.
- The strongest trend for CHRS is in Growth, which has been heading up over the past 179 days.
- CHRS ranks lowest in Stability; there it ranks in the 3rd percentile.
CHRS Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CHRS is -0.93 -- better than just 5.42% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -4.36 for COHERUS BIOSCIENCES INC; that's greater than it is for merely 3.57% of US stocks.
- Revenue growth over the past 12 months for COHERUS BIOSCIENCES INC comes in at -39.61%, a number that bests only 6.24% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to COHERUS BIOSCIENCES INC are AXDX, ASTC, LQDA, TARS, and TTOO.
- Visit CHRS's SEC page to see the company's official filings. To visit the company's web site, go to www.coherus.com.
CHRS Valuation Summary
- In comparison to the median Healthcare stock, CHRS's price/sales ratio is 60.78% lower, now standing at 2.
- CHRS's price/sales ratio has moved down 13.6 over the prior 104 months.
Below are key valuation metrics over time for CHRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CHRS | 2023-05-23 | 2.0 | -1.9 | -1.4 | -3.5 |
| CHRS | 2023-05-22 | 2.0 | -1.8 | -1.3 | -3.4 |
| CHRS | 2023-05-19 | 2.0 | -1.9 | -1.3 | -3.5 |
| CHRS | 2023-05-18 | 2.0 | -1.8 | -1.3 | -3.5 |
| CHRS | 2023-05-17 | 2.2 | -2.1 | -1.5 | -3.6 |
| CHRS | 2023-05-16 | 2.3 | -2.1 | -1.5 | -3.7 |
CHRS Growth Metrics
- The year over year revenue growth rate now stands at -31.41%.
- Its year over year net income to common stockholders growth rate is now at -175.63%.
- The 2 year cash and equivalents growth rate now stands at 68.53%.
The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 239.061 | -193.493 | -278.609 |
| 2022-06-30 | 276.14 | -142.693 | -230.487 |
| 2022-03-31 | 303.632 | -92.844 | -210.237 |
| 2021-12-31 | 326.551 | -37.432 | -287.1 |
| 2021-09-30 | 363.599 | 48.014 | -231.667 |
| 2021-06-30 | 394.647 | 81.656 | -165.206 |
CHRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CHRS has a Quality Grade of B, ranking ahead of 82.07% of graded US stocks.
- CHRS's asset turnover comes in at 0.513 -- ranking 78th of 682 Pharmaceutical Products stocks.
- CPRX, XTNT, and VIVO are the stocks whose asset turnover ratios are most correlated with CHRS.
The table below shows CHRS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.513 | 0.886 | -0.228 |
| 2021-03-31 | 0.572 | 0.913 | -0.075 |
| 2020-12-31 | 0.664 | 0.921 | 0.250 |
| 2020-09-30 | 0.803 | 0.931 | 0.332 |
| 2020-06-30 | 0.995 | 0.936 | 0.477 |
| 2020-03-31 | 1.206 | 0.950 | 0.576 |
CHRS Price Target
For more insight on analysts targets of CHRS, see our CHRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.71 | Average Broker Recommendation | 1.57 (Moderate Buy) |
Coherus BioSciences, Inc. (CHRS) Company Bio
Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.
Latest CHRS News From Around the Web
Below are the latest news stories about COHERUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CHRS as an investment opportunity.
Coherus Announces U.S. Launch of UDENYCA® AutoinjectorUDENYCA Autoinjector UDENYCA® Autoinjector is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need by giving providers a new, innovative option that offers patients greater choice, independence and flexibility – |
Coherus Prices Public Offering of Common StockREDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 1,764,705 shares of its common stock at the public o |
Coherus Announces Proposed Public Offering of Common StockREDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock to be sold in the offering will |
News Flash: 8 Analysts Think Coherus BioSciences, Inc. (NASDAQ:CHRS) Earnings Are Under ThreatOne thing we could say about the analysts on Coherus BioSciences, Inc. ( NASDAQ:CHRS ) - they aren't optimistic, having... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! |
CHRS Price Returns
| 1-mo | -43.56% |
| 3-mo | -41.64% |
| 6-mo | -40.55% |
| 1-year | -44.77% |
| 3-year | -78.50% |
| 5-year | -73.59% |
| YTD | -47.98% |
| 2022 | -50.38% |
| 2021 | -8.17% |
| 2020 | -3.47% |
| 2019 | 98.95% |
| 2018 | 2.84% |
Continue Researching CHRS
Want to do more research on Coherus BioSciences Inc's stock and its price? Try the links below:Coherus BioSciences Inc (CHRS) Stock Price | Nasdaq
Coherus BioSciences Inc (CHRS) Stock Quote, History and News - Yahoo Finance
Coherus BioSciences Inc (CHRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...